Vktx nasdaq

Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -18.74M. -233.36%. Get the latest 89bio Inc (ETNB) real-time quote, historical ....

VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Did you know?

Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...Dec 1, 2023 · Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share). Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

VKTXNASDAQ 12.28USD +0.72 +6.23% At close at Nov 24, 13:58 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast VKTX chart Today …Viking Therapeutics Inc stock price live 13.010, this page displays NASDAQ VKTX stock exchange data. View the VKTX premarket stock price ahead of the market session or assess the after hours quote.Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot …According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...

VKTX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. VIKING THERAPEUTICS, INC. (VKTX) Compare. VIKING THERAPEUTICS, INC. 15.39 ...See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Vktx nasdaq. Possible cause: Not clear vktx nasdaq.

Jun 11, 2021 · Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ... Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viking Therapeutics Inc (Symbol: VKTX), where a total of 11,518 contracts have traded ...Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ...

Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 74% ownership. That ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, the firm's shares ...Find the latest press releases from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

best places to retire in arizona 2023 Shares of clinical-stage biotech Viking Therapeutics ( VKTX 6.68%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ... bloomberg barclays aggregate bond indexhow to invest in lithium stocks Here are three undervalued biotech stocks to consider immediately. CRISPR Therapeutics (CRSP): It could soon bring Exa-cel to market with Vertex Pharmaceuticals. Viking Therapeutics ( VKTX ): A ...Standing squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. This target puts the upside ... icoreconnect stock Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real... SAN DIEGO, Sept. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ... what's the best stock to invest in on cash appsimulated tradingrbc bank stock Viking Therapeutics Inc (NASDAQ:VKTX) 13.01 Delayed Data As of Dec 01 +0.79 / +6.42% Today’s Change 3.54 Today ||| 52-Week Range 25.72 +38.35% Year-to-Date Quote Profile News Charts Forecasts...Latest SEC filings for Viking Therapeutics, Inc. (VKTX). trmd dividend Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...May 16, 2023 · May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ... decker stockunited concordia dental insurance for retired militaryluckin coffe stock Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00. In a report released yesterday, Steven Seedhouse from Raymond James maintained a Buy rating on Viking Therapeutics (VKTX – Research Report... In a report released yesterday, Steven Seedhouse from Raymond James maintained a Buy rating ...